NCT06421675
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Recruiting · Phase 2 · Ontario Clinical Oncology Group (OCOG) · registry updated 2026-09-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
Inclusion
- Relapsed and/or refractory MM defined as:
- Documented evidence of progressive disease (PD) after achieving at least minimal response (MR) for ≥ 1 cycle during a previous MM treatment (i.e., relapsed MM).
- Disease progression during or within 60 days from the end of the most recent MM treatment (i.e., refractory MM).
- Measurable disease based on IMWG criteria, defined as at least one of the following, documented within 28 days before enrollment:
- Serum M-protein ≥ 0.5 g/dl.
- Urine M-protein excretion ≥ 200 mg/24 h.
Exclusion
- Medical conditions
- Active plasma cell leukemia (either 20% of peripheral white blood cells or \> 2.0 × 109/L circulating plasma cells by standard differential).
- Amyloidosis.
- POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, Skin Changes).
- Monoclonal gammopathy of unknown significance or smoldering multiple myeloma.
- Solitary plasmacytoma.